News | May 12, 2025
Dabur India posts Q4 FY25 consolidated PAT at Rs. 320.13 Cr
The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
The FDA issued Form 483 with one observation related to building and facility management
These observations are procedural in nature and none of them are related to data integrity
The Subsidiary has received one inspectional observation in Form 483
The company does not expect this development to have any material impact on the current business operations
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer
Alkem Medtech to acquire 100% stake of Bombay Ortho
Subscribe To Our Newsletter & Stay Updated
